

CORRECTION

Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an *a priori*-designed analysis of the MENDS randomized controlled trial

Pratik P Pandharipande^{1,2}, Robert D Sanders^{*3}, Timothy D Girard^{4,5,6}, Stuart McGrane^{1,2}, Jennifer L Thompson⁷, Ayumi K Shintani⁷, Daniel L Herr⁸, Mervyn Maze⁹, E Wesley Ely^{4,5,6} for the MENDS investigators

See related research by Pandharipande *et al.*, <http://ccforum.com/content/14/2/R38>

After publication of our article [1], we noted typographical errors in our tables and in the labelling of Figure 3. There have been no changes to the results or their interpretation.

In Tables 1, 2 and 3 the number of dexmedetomidine patients without sepsis should read 21 instead of the published 20. The numbers in the corresponding text are correct. The corrected tables can be found overleaf.

In Figure 3, in the "Patients at risk" table below the Kaplan-Meier curve, the dexmedetomidine and lorazepam labels are incorrect. The top row should be labeled lorazepam and the bottom row should be labeled dexmedetomidine. The corrected figure can be found overleaf.

Author Details

¹Anesthesiology Service, VA TN Valley Health Care System, 1310 24th Avenue South, Nashville, TN 37212-2637, USA. ²Department of Anesthesiology, Division of Critical Care, Vanderbilt University School of Medicine; 324 MAB, Nashville, TN 37212-1120, USA. ³Department of Leucocyte Biology & Magill Department of Anaesthetics, Intensive Care and Pain Medicine, Imperial College London, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK. ⁴Department of Medicine, Division of Allergy, Pulmonary,

and Critical Care Medicine, Vanderbilt University School of Medicine; T-1218 MCN, Nashville, TN 37232-2650, USA. ⁵Center for Health Services Research, Vanderbilt University School of Medicine; 6th Floor MCE, Suite 6100, Nashville, TN 37232-8300, USA. ⁶Veterans Affairs Tennessee Valley Geriatric Research, Education, and Clinical Center; 1310 24th Avenue South, Nashville, TN 37212-2637, USA. ⁷Department of Biostatistics, Vanderbilt University School of Medicine; S-2323 MCN, Nashville, TN 37232-2158, USA. ⁸Department of Surgery and Surgical Critical Care, Washington Hospital Center; 110 Irving St NW, Room 4B42, Washington, DC 20010, USA. ⁹Department of Anesthesiology and Perioperative Care, University of California San Francisco; 521 Parnassus Avenue, C455, San Francisco, CA 94143-0648, USA.

Published: 14 January 2011

Reference

1. Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, Herr DL, Maze M, Ely EW; for the MENDS investigators: **Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an *a priori*-designed analysis of the MENDS randomized controlled trial.** *Crit Care* 2010, **14**:R38.

doi:10.1186/cc9416

Cite this article as: Pandharipande PP, *et al.*: Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an *a priori*-designed analysis of the MENDS randomized controlled trial. *Critical Care* 2011, **15**:402.

* Correspondence: robert.sanders@ic.ac.uk

³Department of Leucocyte Biology & Magill Department of Anaesthetics, Intensive Care and Pain Medicine, Imperial College London, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK

Full list of author information is available at the end of the article

Table 1. Baseline characteristics of patients with and without sepsis*

Variable	Patients with sepsis		Patients without sepsis	
	DEX (n = 31)	LZ (n = 32)	DEX (n = 21)	LZ (n = 19)
Age	60 (46, 65)	58 (44, 66)	61 (50, 68)	60 (52, 67)
Males	58%	41%	57%	53%
APACHE II	30 (26, 34)	29 (24, 32)	27 (20, 31)	25 (20, 30)
SOFA score	10 (9,13)	9 (8, 12)	9 (8, 12)	8 (7, 9)
IQCODE at enrollment	3 (3, 3)	3 (3, 3)	3 (3, 3)	3 (3, 3)
Medical ICU	77%	81%	62%	47%
Surgical ICU	23%	19%	38%	53%
Pre-enrollment lorazepam (mg)	1.5 (0, 5)	0 (0, 4)	0 (0, 4)	0 (0, 2)
Enrollment RASS	-3 (-4, -2)	-4 (-4, -3)	-3 (-4, 0)	-3 (-4, -1)
SIRS criteria				
Temperature (Fahrenheit)	37.5 (37, 38.3)	38 (37.2, 38.6)	36.7 (35.8, 37.8)	37.2 (36.2, 38.3)
White blood count (10 ³ /μL)	12.5 (6.6, 21.7)	12.5 (7.7, 18.8)	14.6 (8.9,17.9)	10 (7.5,14)
Systolic BP (mm Hg)	88 (78, 100)	83 (79, 100)	92 (90, 100)	90 (80,110)
Heart rate (per minute)	113 (100, 134)	119 (96, 130)	80 (65,123)	107 (99, 126)
Respiratory rate	26 (20, 33)	33 (27, 39)	20 (15 ,24)	24 (20,28)
Organ dysfunction at enrollment				
PaO ₂ /FiO ₂ ratio	128 (105, 209)	126 (94, 198)	127 (72, 211)	145 (81, 223)
Creatinine (mg/dL)	1.7 (0.8, 2.9)	1.0 (0.8, 1.8)	1.2 (1.0, 1.7)	0.9 (0.8, 1.4)
Vasopressors	32%	56%	19%	5%
Bilirubin (mg/dL)	0.5 (0.4, 0.8)	0.9 (0.4, 1.8)	0.6 (0.5, 1.6)	0.6 (0.4, 1.1)
Platelets (10 ³ /μL)	176 (61, 304)	183 (107, 266)	186 (101,242)	145 (114, 242)

Median (interquartile range) unless otherwise noted

*Abbreviations: DEX, dexmedetomidine; LZ, lorazepam; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment; IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly; ICU, intensive care unit; SIRS, Systemic Inflammatory Response Syndrome; BP, Blood pressure.

Table 2. Outcomes of patients with and without sepsis*

Outcome variable	Patients with sepsis			Patients without sepsis		
	DEX (n = 31)	LZ (n = 32)	Adjusted P value**	DEX (n = 21)	LZ (n = 19)	Adjusted P value**
Duration of Brain Organ Dysfunction						
Delirium/coma-free days**	6.1 (4.3)	2.9 (3.2)	0.005	6 (4.7)	5.5 (3.6)	0.97
Delirium-free days [†]	8.1 (3.1)	6.7(2.9)	0.06	8.1 (3.5)	7.9 (2.8)	0.80
Coma-free days [‡]	9.4 (2.9)	5.9 (4.2)	<0.001	8.9 (4)	8.8 (2.6)	1
Other clinical outcomes						
MV-free days [‡]	15.2 (10.6)	10.1 (10.3)	0.03	12.8 (11.5)	17.2 (10)	0.15
ICU days	13.4 (15.1)	12.2 (9.8)	0.81	14.9 (16.5)	10.4 (8.9)	0.28
28-day mortality	16%	41%	0.03	19%	5%	0.21

Mean (standard deviation) unless otherwise noted

Abbreviations: DEX, dexmedetomidine; LZ, lorazepam; ICU, intensive care unit; MV, mechanical ventilation

*Adjusted P value obtained from the bootstrap multiple linear regression that calculated a difference in mean for each outcome between the two treatment groups, adjusting for age, severity of illness, use of drotrecogin alfa (activated) within 48 hours of enrollment, sepsis, treatment group, and a treatment group by sepsis interaction.

**Indicates the number of days alive without delirium or coma from study day 1 to 12.

[†]Indicates the number of days alive without delirium from study day 1 to 12.

[‡]Indicates the number of days alive without coma from study day 1 to 12.

[§]Indicates the number of days alive breathing without assistance of the ventilator from study day 1 to 28.

Table 3. Hemodynamic parameters in patients with and without sepsis*

Hemodynamic variable**	Patients with sepsis			Patients without sepsis		
	DEX (n = 31)	LZ (n = 32)	P value	DEX (n = 21)	LZ (n = 19)	P value
Number of days on vasoactive drugs	1 (1)	2 (2)	0.08	1.5 (2.2)	0.3 (0.9)	0.08
Average daily number of vasoactive drugs	1.1 (0.2)	1.6 (0.5)	0.004	1.6 (0.9)	1 (0)	0.2
Ever vasoactive drugs increased	26%	47%	0.08	33%	16%	0.2
Sinus bradycardia (< 60 beats/min)	13%	6%	0.4	24%	0%	0.02
Sinus tachycardia (> 100 beats/min)	81%	84%	0.7	52%	53%	1

Mean (standard deviation) unless otherwise noted

*Abbreviations: DEX, dexmedetomidine; LZ, lorazepam

** Measured during 120-hour study drug protocol, except for sinus bradycardia & sinus tachycardia, which are measured during entire study.




Figure 3. Kaplan-Meier curve showing probability of survival during the first 28 days according to treatment group, among patients with sepsis. Dexmedetomidine decreased the probability of dying within 28 days by 70%; this beneficial effect was not seen in patients who were not septic (*P* value for interaction = 0.11 implying an interaction between sepsis and the treatment groups).